Allurion completes enrollment in pivotal audacity trial for the allurion balloon

Natick, mass.--(business wire)--allurion technologies, inc. (nyse: alur), a company dedicated to ending obesity, today announced the completion of patient enrollment in its audacity trial. audacity is a randomized, pivotal controlled trial designed to support u.s. food and drug administration (fda) approval of the allurion balloon. the trial enrolled 550 patients at 17 sites and completed enrollment two months ahead of schedule. “i believe the brisk enrollment in the audacity trial reflects the.
ALUR Ratings Summary
ALUR Quant Ranking